You are here: Industry Insights > opioid

News List

Purdue Pharma to pay $4.5bn to settle opioid lawsuit in the US pharmaceutical-technology
July 12, 2021
Purdue Pharma has agreed to pay more than $4.5bn to resolve a multi-state lawsuit in the US for its alleged role in driving the opioid crisis in the country.
Recommended Therapy for Low Back Pain May Cut Lost Workdays drugs
July 07, 2021
When injured workers with low back pain (LBP) receive guideline-recommended interventions, they typically return to work sooner, according to a study published June 17 in PLOS ONE.
Johnson & Johnson to pay $230m to settle opioid-related claims pharmaceutical-business-review
July 02, 2021
Johnson & Johnson (J&J) has reached a $230m agreement to settle the opioid-related claims with the New York State and its participating subdivisions Nassau County and Suffolk County.
J&J ends sales of opioids in the US, reaches settlement deal with New York firstwordpharma
June 28, 2021
Johnson & Johnson disclosed alongside a settlement agreement with the State of New York that it stopped selling prescription pain medicines in the US last year, having ceased marketing of the products in 2015.
Adamis Provides Update on Zimhi drugs
June 21, 2021
Adamis Pharmaceuticals Corporation today announced that the FDA has accepted for review the Company’s resubmitted New Drug Application (NDA) for ZIMHI™, which is its higher naloxone injection product candidate for the treatment of opioid overdose.
Could medicinal cannabis be the answer to the opioid crisis? europeanpharmaceuticalreview
May 31, 2021
New data from the UK shows 86 percent of pain patients found medicinal cannabis more effective than and other medication, including opioids.
Duloxetine Cuts Opioid Use After Total Knee Arthroplasty drugs
May 26, 2021
As part of a multimodal analgesic regimen in patients undergoing total knee arthroplasty, duloxetine cuts opioid use compared with placebo, according to a study presented at the annual Regional Anesthesiology and Acute Pain Medicine Meeting
Adamis Pharmaceuticals Resubmits Zimhi New Drug Application to FDA for the Treatment of Opioid Overdose drugs
May 20, 2021
Adamis Pharmaceuticals Corporation，today announced that the New Drug Application (NDA) was resubmitted to the U.S. Food and Drug Administration (FDA) for Zimhi™, a naloxone injection product candidate intended for the treatment of opioid overdose.
Hikma Pharma get US FDA nod for higher dosage of nasal spray product to treat opioid overdose expresspharma
May 07, 2021
The US Food and Drug Administration (US FDA) announced the approval of a higher dose naloxone hydrochloride nasal spray product to treat opioid overdose.
Hikma get US FDA nod for higher dosage of naloxone nasal spray to treat opioid overdose expresspharma
May 07, 2021
The US Food and Drug Administration (US FDA) announced the approval of a higher dose naloxone hydrochloride nasal spray product to treat opioid overdose.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 21 22 Next page